Determine the necessary mass, volume, or concentration for preparing a solution.
Dezamizumab (anti-Serum Amyloid P) (Ab175509) - SEC
The purity of Dezamizumab (anti-Serum Amyloid P) (Ab175509) is more than 95% verified by HPLC.
SKU | Size | Availability | Price | Qty |
---|---|---|---|---|
Ab175509-100μg | 100μg | In stock | $109.90 | |
Ab175509-1mg | 1mg | In stock | $519.90 | |
Ab175509-5mg | 5mg | In stock | $1,399.90 | |
Ab175509-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $2,239.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Product Name | Dezamizumab (anti-Serum Amyloid P) - Primary antibody, specific to APCS, >95%, high purity, Human IgG1 |
---|---|
Synonyms | 9.5S alpha 1 glycoprotein antibody | 9.5S alpha-1-glycoprotein antibody | Amyloid P component serum antibody | APCS antibody | MGC88159 antibody | Pentaxin related antibody | Pentraxin 2 antibody | PTX 2 antibody | PTX2 antibody | SAMP_HUMAN antibody | SA |
Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
Host species | Human |
Specificity | APCS |
Conjugation | Unconjugated |
Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
Action Type | INHIBITOR |
Mechanism of action | Antibody of amyloid P component; serum |
Product Description | Dezamizumab (anti-Serum Amyloid P) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody, with potential anti-amyloid activity. Dezamizumab (anti-Serum Amyloid P) triggers immunotherapeutic clearance of amyloid. Dezamizumab (anti-Serum Amyloid P) can be used in research of Amyloid light-chain (AL) amyloidosis. |
Isotype | Human IgG1 |
---|---|
Light Chain Type | kappa |
SDS-PAGE | 26.3 kDa (Light Chain) & 51.3 kDa (Heavy Chain), under reducing conditions; 191.2 kDa, under non-reducing conditions. |
Purification Method | Protein A purified |
Purity | >95% |
Form | Liquid |
Concentration | Lot by Lot |
Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
Shipped In | Ice chest + Ice pads |
Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
CAS | 1662664-56-3 |
Dezamizumab (anti-Serum Amyloid P) (Ab175509) - SEC
The purity of Dezamizumab (anti-Serum Amyloid P) (Ab175509) is more than 95% verified by HPLC.
Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Enter Lot Number to search for COA:
Find and download the COA for your product by matching the lot number on the packaging.
Lot Number | Certificate Type | Date | Item |
---|---|---|---|
ZJ24F0303108 | Certificate of Analysis | Mar 12, 2024 | Ab175509 |
ZJ24F0303107 | Certificate of Analysis | Mar 12, 2024 | Ab175509 |
ZJ24F0303106 | Certificate of Analysis | Mar 12, 2024 | Ab175509 |
1. Tennent GA, Lovat LB, Pepys MB. (1995) Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer disease and systemic amyloidosis.. Proc Natl Acad Sci USA, 92 (10): (4299-303). [PMID:7753801] [10.1021/op500134e] |
2. Botto M, Hawkins PN, Bickerstaff MC, Herbert J, Bygrave AE, McBride A, Hutchinson WL, Tennent GA, Walport MJ, Pepys MB. (1997) Amyloid deposition is delayed in mice with targeted deletion of the serum amyloid P component gene.. Nat Med, 3 (8): (855-9). [PMID:9256275] [10.1021/op500134e] |
3. Bodin K, Ellmerich S, Kahan MC, Tennent GA, Loesch A, Gilbertson JA, Hutchinson WL, Mangione PP, Gallimore JR, Millar DJ et al.. (2010) Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.. Nature, 468 (7320): (93-7). [PMID:20962779] [10.1021/op500134e] |
4. Mantzouranis EC, Dowton SB, Whitehead AS, Edge MD, Bruns GA, Colten HR. (1985) Human serum amyloid P component. cDNA isolation, complete sequence of pre-serum amyloid P component, and localization of the gene to chromosome 1.. J Biol Chem, 260 (12): (7752-6). [PMID:2987268] [10.1021/op500134e] |
5. Ohnishi S, Maeda S, Shimada K, Arao T. (1986) Isolation and characterization of the complete complementary and genomic DNA sequences of human serum amyloid P component.. J Biochem, 100 (4): (849-58). [PMID:3029048] [10.1021/op500134e] |
6. Thompson, A R AR and Enfield, D L DL.. (1978) Human plasma P component: isolation and characterization.. Biochemistry, (3): [PMID:81686] |
7. Prelli, F F, Pras, M M and Frangione, B B.. (1985) The primary structure of human tissue amyloid P component from a patient with primary idiopathic amyloidosis.. The Journal of biological chemistry, (25): [PMID:4055725] |
8. Emsley, J J and 8 more authors.. (1994) Structure of pentameric human serum amyloid P component.. Nature, (27): [PMID:8114934] |
9. Pepys, M B MB and 9 more authors.. (1994) Human serum amyloid P component is an invariant constituent of amyloid deposits and has a uniquely homogeneous glycostructure.. Proceedings of the National Academy of Sciences of the United States of America, (7): [PMID:8202534] |
10. Hohenester, E E, Hutchinson, W L WL, Pepys, M B MB and Wood, S P SP.. (1997) Crystal structure of a decameric complex of human serum amyloid P component with bound dAMP.. Journal of molecular biology, (20): [PMID:9217261] |
11. Kiernan, Urban A UA, Nedelkov, Dobrin D, Tubbs, Kemmons A KA, Niederkofler, Eric E EE and Nelson, Randball W RW.. (2004) Proteomic characterization of novel serum amyloid P component variants from human plasma and urine.. Proteomics, [PMID:15174148] |
12. Liu, Tao T and 6 more authors.. () Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry.. Journal of proteome research, [PMID:16335952] |